A Phase 3 interventional study of Alogliptin and Metformin hydrochloride in Type 2 Diabetes Mellitus, sponsored by Takeda. Completed at 27 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 60th largest by enrollment of the 287 interventional ones that give a count, is one of 16 that started in 2014, is one of 72 in phase 3, and was the 188th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 16 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 374 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
105 studies in Diabetes Mellitus, Type 2 by Takeda: none open now, none under way, none of them phase 3. Of 103 finished, 69 (67%) have results posted.
Among the 105 studies in Diabetes Mellitus, Type 2 by Takeda, this one is the 37th largest by enrollment of the 85 interventional ones that give a count, is one of 7 that started in 2014, is one of 45 in phase 3, and was the 82nd registered.
Takeda’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
Among Takeda’s 105 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the efficacy and safety of 24-week treatment with metformin hydrochloride 500 mg once daily added on to alogliptin (SYR-322) 25 mg in type 2 diabetic patients with inadequate glycemic control despite treatment with alogliptin 25 mg in addition to diet and exercise therapy.
The drugs being tested in this study are called alogliptin and metformin hydrochloride. Alogliptin in combination with metformin hydrochloride was being tested to treat people who have Type 2 diabetes mellitus (T2DM) with inadequate glycemic control despite treatment with alogliptin in addition to diet and exercise. This study looked at the efficacy and safety of alogliptin 25 mg once daily (QD) + metformin hydrochloride 500 mg QD compared to alogliptin 25 mg QD + metformin hydrochloride 250 mg twice daily (BID) and alogliptin 25 mg QD administered alone.
The study enrolled 374 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):
This multi-center trial was conducted in Japan. The overall time to participate in this study was 36 weeks (12-week screening period and 24-week treatment period). Participants made multiple visits to the clinic including a final visit 24 weeks after the start of study medication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride placebo-matching, tablets, orally, 2 tablets after breakfast and 1 tablet after dinner for 24 weeks.
Drug: Alogliptin · Drug: Metformin hydrochloride Placebo
Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 500 mg QD (250 mg x 2 tablets, once daily), tablets, orally, once, daily, after breakfast and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after dinner for 24 weeks.
Drug: Alogliptin · Drug: Metformin hydrochloride · Drug: Metformin hydrochloride Placebo
Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 250 mg BID (twice daily), tablets, orally, 1 tablet after breakfast and 1 tablet after dinner and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after breakfast for 24 weeks.
Drug: Alogliptin · Drug: Metformin hydrochloride · Drug: Metformin hydrochloride Placebo
Alogliptin tablets
Also known as: SYR-322, Nesina®
Metformin hydrochloride tablets
Also known as: Glycoran®
Metformin hydrochloride placebo-matching tablets
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) National Glycohemoglobin Standardization Program (NGSP) at the End of Treatment (EOT) Period
The change in the value of HbA1c (NGSP) (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at End of Treatment Period relative to Baseline. A negative change from Baseline indicates improvement. An Analysis of Covariate (ANCOVA) model with change from Baseline as a dependent variable and Baseline and treatment as independent variables was used for main analyses.
Time frame: Baseline and End of Treatment (EOT) (Up to Week 24)
Change From Baseline in HbA1c (NGSP)
The change in the value of HbA1c (NGSP) (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Weeks 2, 4, 8, 12, 16, 20, 24, and EOT relative to Baseline. A negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24 and EOT (Up to Week 24)
HbA1c (NGSP)
The value of HbA1c (NGSP) (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, and EOT.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24 and EOT (Up to Week 24)
Percentage of Participants Achieving Target HbA1c (NGSP) Levels at the EOT Period
HbA1c (NGSP) is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound. The percentage of participants with HbA1c levels of ≥6.0, ≥7.0 and ≥8.0 at the end of Screening (Baseline) with change to target values \<6.0, \<7.0 and \<8.0 respectively at EOT.
Time frame: Baseline and EOT (Up to Week 24)
Change From Baseline in Fasting Blood Glucose
The change in the value of the fasting plasma glucose collected at Weeks 2, 4, 8, 12, 16, 20 and 24 relative to Baseline. A negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24 and EOT (Up to Week 24)
Fasting Blood Glucose
The value of the fasting plasma glucose collected at Baseline and Weeks 2, 4, 8, 12, 16, 20, 24 and EOT.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24 and EOT (Up to Week 24)
Percentage of Participants With Treatment-Emergent Adverse Events (TEAE)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: 24 Weeks
Percentage of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis
The percentage of participants with any clinically relevant safety laboratory changes (chemistry, hematology and urinalysis) collected throughout study and recorded as AEs.
Time frame: 24 Weeks
Percentage of Participants With TEAEs Related to Vital Signs
Vital signs included sitting systolic and diastolic blood pressures (mmHg) (measured after resting for ≥ 5 minutes) and pulse rate (beats per minute \[bpm\]).
Time frame: 24 Weeks
Number of Participants Who Had Clinically Relevant Changes in 12-Lead Electrocardiogram (ECG) Findings
Number of participants who had ECG findings changed from "normal" or "abnormal but not clinically relevant" at Baseline to "abnormal and clinically relevant".
Time frame: Baseline and Weeks 12 and 24
Participants took part in the study at 34 investigative sites in Japan from 06 February 2014 (first patient to sign the informed consent form) to 28 February 2015.
| Milestone | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| Started | 71 | 152 | 151 |
| Completed | 64 | 146 | 148 |
| Not completed | 7 | 6 | 3 |
| Withdrew: Pretreatment event/adverse event | 0 | 5 | 2 |
| Withdrew: Voluntary withdrawal | 4 | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 1 | 0 |
| Withdrew: Other reason not specified | 1 | 0 | 0 |
The change in the value of HbA1c (NGSP) (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at End of Treatment Period relative to Baseline. A negative change from Baseline indicates improvement. An Analysis of Covariate (ANCOVA) model with change from Baseline as a dependent variable and Baseline and treatment as independent variables was used for main analyses.
| percent | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) National Glycohemoglobin Standardization Program (NGSP) at the End of Treatment (EOT) Period | 0.16 ± 0.072 | -0.49 ± 0.049 | -0.60 ± 0.049 |
The change in the value of HbA1c (NGSP) (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Weeks 2, 4, 8, 12, 16, 20, 24, and EOT relative to Baseline. A negative change from Baseline indicates improvement.
| percent | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| Week 2 (n=71, 152, 151) | 0.01 ± 0.197 | -0.14 ± 0.203 | -0.19 ± 0.212 |
| Week 4 (n=70, 150, 150) | 0.01 ± 0.316 | -0.28 ± 0.279 | -0.35 ± 0.298 |
| Week 8 (n=68, 149, 149) | -0.01 ± 0.402 | -0.50 ± 0.408 | -0.60 ± 0.454 |
| Week 12 (n=67, 148, 148) | -0.02 ± 0.518 | -0.61 ± 0.530 | -0.75 ± 0.565 |
| Week 16 (n=66, 148, 147) | 0.01 ± 0.543 | -0.64 ± 0.553 | -0.81 ± 0.602 |
| Week 20 (n=65, 146, 148) | 0.11 ± 0.568 | -0.58 ± 0.585 | -0.71 ± 0.626 |
| Week 24 (n=64, 146, 148) | 0.17 ± 0.628 | -0.49 ± 0.629 | -0.62 ± 0.659 |
| EOT (n=71, 152, 151) | 0.17 ± 0.616 | -0.49 ± 0.620 | -0.62 ± 0.654 |
The value of HbA1c (NGSP) (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, and EOT.
| percent | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| Baseline (n=71, 152, 151) | 7.77 ± 0.780 | 7.82 ± 0.820 | 7.89 ± 0.791 |
| Week 2 (n=71, 152, 151) | 7.78 ± 0.824 | 7.67 ± 0.796 | 7.70 ± 0.787 |
| Week 4 (n=70, 150, 150) | 7.78 ± 0.913 | 7.55 ± 0.773 | 7.54 ± 0.735 |
| Week 8 (n=68, 149, 149) | 7.72 ± 0.889 | 7.32 ± 0.725 | 7.28 ± 0.707 |
| Week 12 (n=67, 148, 148) | 7.70 ± 0.987 | 7.19 ± 0.721 | 7.13 ± 0.706 |
| Week 16 (n=66, 148, 147) | 7.70 ± 0.990 | 7.16 ± 0.725 | 7.08 ± 0.717 |
| Week 20 (n=65, 146, 148) | 7.81 ± 1.023 | 7.23 ± 0.749 | 7.18 ± 0.780 |
| Week 24 (n=64, 146, 148) | 7.86 ± 0.983 | 7.32 ± 0.798 | 7.27 ± 0.805 |
| EOT (n=71, 152, 151) | 7.95 ± 1.018 | 7.33 ± 0.819 | 7.28 ± 0.804 |
HbA1c (NGSP) is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound. The percentage of participants with HbA1c levels of ≥6.0, ≥7.0 and ≥8.0 at the end of Screening (Baseline) with change to target values \<6.0, \<7.0 and \<8.0 respectively at EOT.
| percentage of participants | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| ≥6.0 at Baseline to <6.0 at EOT (n=71, 152, 151) | 0.0 (0.197 to —) | 0.7 (0.203 to —) | 1.3 (0.212 to —) |
| ≥7.0 at Baseline to <7.0 at EOT ( n=63, 137, 140) | 4.8 (0.316 to —) | 35.0 (0.279 to —) | 34.3 (0.298 to —) |
| ≥8.0 at Baseline to <8.0 at EOT (n=26, 59, 64) | 23.1 (0.402 to —) | 47.5 (0.408 to —) | 60.9 (0.454 to —) |
The change in the value of the fasting plasma glucose collected at Weeks 2, 4, 8, 12, 16, 20 and 24 relative to Baseline. A negative change from Baseline indicates improvement.
| mg/dL | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| Week 2 (n=71, 152, 151) | 0.4 ± 16.62 | -16.6 ± 18.99 | -23.7 ± 20.50 |
| Week 4 (n=70, 150, 150) | -0.9 ± 26.32 | -16.4 ± 20.79 | -25.2 ± 20.73 |
| Week 8 (n=68, 149, 149) | -2.1 ± 23.30 | -18.4 ± 20.90 | -23.4 ± 24.13 |
| Week 12 (n=67, 148, 148) | 1.5 ± 20.42 | -15.2 ± 23.83 | -22.9 ± 24.36 |
| Week 16 (n=66, 148, 148) | 0.4 ± 22.63 | -13.0 ± 24.70 | -22.6 ± 25.50 |
| Week 20 (n=65, 146, 148) | 6.6 ± 23.87 | -11.3 ± 23.34 | -17.6 ± 25.25 |
| Week 24 (n=64, 146, 148) | 8.0 ± 21.85 | -7.2 ± 26.53 | -18.2 ± 25.28 |
| EOT (n=71, 152, 151) | 7.4 ± 26.89 | -7.6 ± 26.41 | -18.2 ± 25.41 |
The value of the fasting plasma glucose collected at Baseline and Weeks 2, 4, 8, 12, 16, 20, 24 and EOT.
| mg/dL | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| Baseline (n=71, 152, 151) | 162.4 ± 31.03 | 164.7 ± 31.02 | 165.9 ± 30.92 |
| Week 2 (n=71, 152, 151) | 162.8 ± 33.42 | 148.1 ± 26.70 | 142.3 ± 25.24 |
| Week 4 (n=70, 150, 150) | 161.4 ± 37.17 | 148.7 ± 27.56 | 140.7 ± 23.74 |
| Week 8 (n=68, 149, 149) | 158.9 ± 33.15 | 146.5 ± 25.21 | 142.0 ± 25.35 |
| Week 12 (n=67, 148, 148) | 161.1 ± 33.43 | 149.2 ± 30.70 | 142.5 ± 27.85 |
| Week 16 (n=66, 148, 148) | 158.5 ± 29.71 | 151.4 ± 32.52 | 142.9 ± 26.16 |
| Week 20 (n=65, 146, 148) | 164.6 ± 31.64 | 153.2 ± 30.92 | 147.8 ± 28.21 |
| Week 24 (n=64, 146, 148) | 165.9 ± 31.19 | 157.4 ± 33.21 | 147.3 ± 26.85 |
| EOT (n=71, 152, 151) | 169.8 ± 36.03 | 157.1 ± 32.82 | 147.7 ± 27.20 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| percentage of participants | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) | 57.7 | 50.7 | 52.3 |
The percentage of participants with any clinically relevant safety laboratory changes (chemistry, hematology and urinalysis) collected throughout study and recorded as AEs.
| percentage of participants | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| Blood Creatine Phosphokinase increased | 0 | 2.0 | 0.7 |
| Blood Lactic Acid increased | 0 | 1.3 | 0 |
| Amylase increased | 0 | 0 | 2.0 |
| Lipase increased | 0 | 0 | 2.0 |
| Blood Albumin decreased | 0 | 0 | 0.7 |
| Gamma-glutamyltransferase increased | 0 | 0 | 0.7 |
Vital signs included sitting systolic and diastolic blood pressures (mmHg) (measured after resting for ≥ 5 minutes) and pulse rate (beats per minute \[bpm\]).
| percentage of participants | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| Hypertension | 1.4 | 0 | 0 |
| Blood Pressure increased | 0 | 0 | 0.7 |
Number of participants who had ECG findings changed from "normal" or "abnormal but not clinically relevant" at Baseline to "abnormal and clinically relevant".
| participants | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| Week 12 | 0 | 0 | 0 |
| Week 24 | 0 | 0 | 2 |
Collected over 24 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alogliptin Alone | — | 1/71 (1.4%) | 15/71 (21.1%) |
| Alogliptin + Metformin Hydrochloride QD | — | 3/152 (2%) | 25/152 (16.4%) |
| Alogliptin + Metformin Hydrochloride BID | — | 0/151 (0%) | 27/151 (17.9%) |
| Event | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| DiverticulitisInfections and infestations | 1/71 | 0/152 | 0/151 |
| Brain contusionInjury, poisoning and procedural complications | 0/71 | 1/152 | 0/151 |
| ContusionInjury, poisoning and procedural complications | 0/71 | 1/152 | 0/151 |
| FallInjury, poisoning and procedural complications | 0/71 | 1/152 | 0/151 |
| Fibula fractureInjury, poisoning and procedural complications | 0/71 | 1/152 | 0/151 |
| Limb crushing injuryInjury, poisoning and procedural complications | 0/71 | 1/152 | 0/151 |
| Pulmonary contusionInjury, poisoning and procedural complications | 0/71 | 1/152 | 0/151 |
| Rib fractureInjury, poisoning and procedural complications | 0/71 | 1/152 | 0/151 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/71 | 1/152 | 0/151 |
| Scapula fractureInjury, poisoning and procedural complications | 0/71 | 1/152 | 0/151 |
| Event | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/71 | 22/152 | 19/151 |
| PharyngitisInfections and infestations | 3/71 | 3/152 | 9/151 |
| HypoaesthesiaNervous system disorders | 4/71 | 1/152 | 0/151 |
All randomized participants.
| Age, Continuous(years) | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID | Total |
|---|---|---|---|---|
| Mean | 57.2 ± 10.07 | 56.9 ± 8.79 | 57.6 ± 9.72 | 57.2 ± 9.40 |
| Age, Customized(participants) | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID | Total |
|---|---|---|---|---|
| < 65 years | 52 | 119 | 109 | 280 |
| ≥ 65 years | 19 | 33 | 42 | 94 |
| Sex: Female, Male(Participants) | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID | Total |
|---|---|---|---|---|
| Female | 19 | 42 | 45 | 106 |
| Male | 52 | 110 | 106 | 268 |
| Region of Enrollment(participants) | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID | Total |
|---|---|---|---|---|
| Japan | 71 | 152 | 151 | 374 |
| Height(cm) | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID | Total |
|---|---|---|---|---|
| Mean | 165.3 ± 8.89 | 164.6 ± 8.82 | 164.6 ± 9.12 | 164.8 ± 8.94 |
| Body Weight(kg) | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID | Total |
|---|---|---|---|---|
| Mean | 68.00 ± 13.702 | 69.48 ± 13.074 | 69.55 ± 14.927 | 69.23 ± 13.943 |
| Body Mass Index (BMI)(kg/m^2) | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID | Total |
|---|---|---|---|---|
| Mean | 24.72 ± 3.764 | 25.61 ± 4.231 | 25.52 ± 4.344 | 25.41 ± 4.196 |
| Duration of Type 2 Diabetes(years) | Alogliptin Alone | Alogliptin + Metformin Hydrochloride QD | Alogliptin + Metformin Hydrochloride BID | Total |
|---|---|---|---|---|
| Mean | 7.73 ± 4.666 | 7.02 ± 5.257 | 7.04 ± 5.380 | 7.16 ± 5.195 |
7 further baseline measures are reported on the registry.
The record gives a start of Feb 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin